CDLX

Cardlytics is a broken growth story trading like an option on survival. Revenue fell 16.9% in FY2025 to $212M — the fourth consecutive year of stagnation-then-decline (from a $285M peak in FY2023), driven by the exact dynamic management flags in the MD&A: GAAP revenue is reported net of Consumer Incentives, so as partners fund richer incentives to boost engagement, reported revenue is mechanically depressed. Losses remain enormous (-$103M net, -48% net and operating margins), and the accumulated deficit of -$1.40B has pushed stockholders' equity negative (-$6.5M), leaving liabilities/equity meaningless at -44.9x. This is not a healthy business by any fundamental measure.

The reason this is a 'hold' rather than an 'avoid' is that the picture is stabilizing at the cash and price level. The FY2025 net loss narrowed 45% YoY, operating cash flow swung positive to +$9.3M (from deeply negative), and capex is negligible ($0.5M), so the company is roughly self-funding operations for the first time. Long-term debt of $213M against just $48.7M cash is the real overhang, but there is no current portion due ($0 short-term borrowings) and current assets ($137M) comfortably exceed current liabilities ($78.4M) for a 1.75x current ratio — no imminent liquidity cliff. At $4.47 the market cap is only $246M, or 1.2x sales, pricing in continued decline.